Duchesne GM - Search Results

1

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy.

Stensland KD, Devasia T, Caram MEV, Chapman C, Zaslavsky A, Morgan TM, Hollenbeck BK, Sparks JB, Burns J, Vedapudi V, Duchesne GM, Tsodikov A, Skolarus TA. Stensland KD, et al. Among authors: duchesne gm. JNCI Cancer Spectr. 2022 May 2;6(3):pkac025. doi: 10.1093/jncics/pkac025. JNCI Cancer Spectr. 2022. PMID: 35616109 Free PMC article.

2

A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?

Tang JI, Williams SG, Tai KH, Dean J, Duchesne GM. Tang JI, et al. Among authors: duchesne gm. Brachytherapy. 2006 Oct-Dec;5(4):256-61. doi: 10.1016/j.brachy.2006.08.007. Brachytherapy. 2006. PMID: 17118320 Clinical Trial.

3

Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.

Williams S, Buyyounouski M, Kestin L, Duchesne G, Pickles T. Williams S, et al. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):724-31. doi: 10.1016/j.ijrobp.2009.11.044. Epub 2010 May 14. Int J Radiat Oncol Biol Phys. 2011. PMID: 20472361

4

Tribulations of a prostate cancer trial – lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial.

Duchesne GM, Woo HH, Howell D, Kaimakamis M, Kemp E. Duchesne GM, et al. J Med Imaging Radiat Oncol. 2010 Oct;54(5):508-11. doi: 10.1111/j.1754-9485.2010.02204.x. J Med Imaging Radiat Oncol. 2010. PMID: 20976993

5

High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.

Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, See A, Duchesne GM. Barkati M, et al. Among authors: duchesne gm. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1889-96. doi: 10.1016/j.ijrobp.2010.09.006. Epub 2011 May 6. Int J Radiat Oncol Biol Phys. 2012. PMID: 21550182 Clinical Trial.

6

Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.

Khor R, Duchesne G, Tai KH, Foroudi F, Chander S, Van Dyk S, Garth M, Williams S. Khor R, et al. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85. doi: 10.1016/j.ijrobp.2012.07.006. Epub 2012 Sep 3. Int J Radiat Oncol Biol Phys. 2013. PMID: 22954770

7

The 'Timing of Androgen-Deprivation therapy in incurable prostate cancer' protocol (TOAD)--where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial.

Duchesne GM, Woo HH. Duchesne GM, et al. BJU Int. 2014 Nov;114 Suppl 1:9-12. doi: 10.1111/bju.12864. BJU Int. 2014. PMID: 25047091 Review.

8

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Denham JW, et al. Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14. Lancet Oncol. 2014. PMID: 25130995 Clinical Trial.

9

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith RG, Spry N, Stockler M, Syme RA, Tai KH, Turner S. Duchesne GM, et al. Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4. Lancet Oncol. 2016. PMID: 27155740 Clinical Trial.

10

Timing of androgen-deprivation therapy for prostate cancer: still a long way to go - Authors' reply.

Duchesne GM. Duchesne GM. Lancet Oncol. 2016 Aug;17(8):e313-e314. doi: 10.1016/S1470-2045(16)30282-0. Lancet Oncol. 2016. PMID: 27511148 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page